最新ニュース Zahav (OTC:ZAHA) 株価情報

Zahav Inc

WIIM

NTNX

Nutanix shares are trading higher after the company reported better-than-expected Q1 financial results.

<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmaximus.com&amp;esheet=54158662&amp;newsitemid=20241126053073&amp;lan=en-US&amp;anchor=Maximus&amp;index=1&amp;md5=a7d9f87c1b7dd3fbe9a85187dc328bbe">Maximus</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>), a leading employer and provider of government services worldwide, announced the U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services (CMS) notified Maximus they have cancelled the Contact Center Operations (CCO) 1-800-MEDICARE and Federal Marketplace solicitation which covered the same scope of work Maximus currently performs under contract today through option periods available until 2031.</p>


Biotech

News

General

U.S. Department Of Health And Human Services, Centers For Medicare And Medicaid Services Notify Maximus Of Cancellation Of The Contact Center Operations Contract Re-Procurement

HP shares are trading lower following weak guidance.

<p>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) provided an update on the planned divestiture of Commonwealth Health System in Pennsylvania.</p>
<p>On November 22, 2024, CHS/Community Health Systems, Inc. ("CHS"), a wholly-owned subsidiary of Community Health Systems, Inc. (the "Company"), and WoodBridge Healthcare, Inc. ("WoodBridge") mutually agreed to terminate the Asset Purchase Agreement dated July 30, 2024, as amended (the "Purchase Agreement"), between CHS and certain wholly-owned subsidiaries (the "CHS Selling Entities") and WoodBridge and certain of its affiliates.</p>
<p>Under the terms of the Purchase Agreement (which was previously disclosed on a Current Report on Form 8-K filed by the Company on July 30, 2024), WoodBridge would have acquired substantially all of the assets of, and assumed certain liabilities from, the CHS Selling Entities related to Regional Hospital of Scranton in Scranton, Pennsylvania, Moses Taylor Hospital in Scranton, Pennsylvania, and Wilkes-Barre General Hospital in Wilkes-Barre, Pennsylvania, and certain related businesses.</p>


Contracts

Community Health Systems Provides Update Regarding Commonwealth Health System; CHS/Community Health Systems And Woodbridge Healthcare Mutually Agreed To Terminate The Asset Purchase Agreement Dated July 30, 2024, As Amended Between CHS And Certain Wholly-Owned Subsidiaries And Woodbridge And Certain Of Its Affiliates.

<p>The earnings results for <strong>Workday</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) for Q3 were made public on Tuesday, November 26, 2024 at 04:01 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Workday beat estimated earnings by 7.000000000000001%, reporting an EPS of $1.89 versus an estimate of $1.76.</p>
<p>Revenue was up $294.00 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.1, resulting in a 12.0% increase change in the share price the following day.</p>
<p>Here's a look at Workday's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.65</td>
<td>1.58</td>
<td>1.47</td>
<td>1.41</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.75</td>
<td>1.74</td>
<td>1.57</td>
<td>1.53</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.07B</td>
<td>1.97B</td>
<td>1.92B</td>
<td>1.85B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.08B</td>
<td>1.99B</td>
<td>1.92B</td>
<td>1.87B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Workday <a href="https://www.benzinga.com/quote/WDAY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

WDAY

Workday: Q3 Earnings Insights

<p><strong>Nutanix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) just disclosed its Q1 earnings on Tuesday, November 26, 2024 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Nutanix beat estimated earnings by 31.0%, reporting an EPS of $0.42 versus an estimate of $0.32.</p>
<p>Revenue was up $79.90 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.07, resulting in a 20.0% increase change in the share price the following day.</p>
<p>Here's a look at Nutanix's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.20</td>
<td>0.16</td>
<td>0.29</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.27</td>
<td>0.28</td>
<td>0.46</td>
<td>0.29</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>536.94M</td>
<td>516.18M</td>
<td>551.34M</td>
<td>501.32M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>547.95M</td>
<td>524.58M</td>
<td>565.23M</td>
<td>511.05M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Nutanix <a href="https://www.benzinga.com/quote/NTNX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Nutanix Q1 Earnings

Guidance

Nordstrom Continues To Expect FY24 Adjusted EPS Of $1.75 - $2.05 (Est $1.89)

DELL

Dell Technologies shares are trading lower following a Q3 revenue miss.

Workday shares are trading lower after the company revised its FY25 subscription revenue guidance,

<p>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) ("NKGen" or the "Company"), today announced it received a notice (the "Notice") on November 20, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule") because it had not timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Form 10-Q") with the Securities and Exchange Commission (the "SEC") on or before November 19, 2024, the extended period provided for the filing under Rule 12b-25(b) of the Securities Exchange Act of 1934, as amended. The delay is in part due to the additional time required for valuation and review of various derivative securities as the Company has taken on more reporting responsibility internally. The Notice from Nasdaq has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Market.</p>
<p>The Company is actively working with its auditors and advisors and intends to file the Form 10-Q as promptly as possible.</p>
<p>On November 20, 2024, subsequent to the Company's receipt of the Notice, the Company received a letter from Nasdaq (the "Decision Letter") granting a temporary exception to the Rule and the minimum market value of listed securities requirement in Nasdaq Listing Rule 5450(b)(2)(A) (the "MVLS Rule") until January 7, 2025. The Seoul Bankruptcy Court (the "Court") is expected to announce its decision on the rehabilitation of NKMax Co. Ltd ("NKMax") and the Company's proposal to acquire a majority interest in NKMax on or before such date. In accordance with the Decision Letter, the Company must advise the Nasdaq Hearings Panel (the "Panel") of the outcome of the Court's decision. If the Company is successful in its bid to acquire a majority interest in NKMax, the Company must advise the Panel no later than January 7, 2025, on its plan for regaining compliance with the Rule and MVLS Rule, for the Panel's further consideration.</p>
<p>The Company may request that the Nasdaq Listing and Hearing Review Council (the "Council") review the Panel's determination in the Decision Letter, by written request received by the Council by December 5, 2024. In such event, the Company would be required to submit a fee of $15,000.00 to Nasdaq to cover the cost of the review. The Council may determine to review any Panel decision by January 4, 2025. The Company does not intend to appeal the Decision Letter at this time and intends to deliver an updated plan of compliance to the Panel no later than January 7, 2025.</p>


NKGN

NKGen Biotech Receives Notifications From Nasdaq Related To Delayed Quarterly Report And Decision Of The Nasdaq Hearings Panel; The Company Does Not Intend To Appeal The Decision Letter At This Time And Intends To Deliver An Updated Plan Of Compliance To The Panel No Later Than January 7, 2025.

<p>For fiscal 2025, HP anticipates generating free cash flow in the range of $3.2 to $3.6 billion.</p>


HP Expects Adj EPS Of $0.70 - $0.76 For Q1 (Est $0.85); $3.45 - $3.75 For FY25 (Est $3.60)

Guess Sees FY25 EPS $0.70-$0.82; Adj. EPS $1.85-$2.00.

<p><a href="https://www.globenewswire.com/Tracker?data=RStI-Eh5ZELBq7ZL7G-QBxlErYxTLAPvtV51a1k8H3KnWszbj2ti19uebhw7GWFQ3ce_q6rFvE8kHIB45a22cePjTzLcXiJ3Yvs4Bydq8dE=">Middlesex Water Company</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSEX#NASDAQ">MSEX</a>), a provider of water and wastewater and related services primarily in New Jersey and Delaware, today announced that Gregory Sorensen has been named as its Vice President and Chief Operating Officer, effective December 16, 2024, as part of ongoing strategic succession planning and organizational realignment efforts.</p>


Management

MSEX

Middlesex Water Names Gregory Sorensen VP And COO, Effective December 16, 2024, As Part Of Ongoing Strategic Succession Planning And Organizational Realignment Efforts.

<p>Regional Health Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RHE#AMEX">RHE</a>) reported quarterly losses of $(0.52) per share. This is unchanged from the same period last year.  The company reported $4.22 million in sales this quarter. This is a 2.10 percent increase over sales of $4.14 million the same period last year.</p>


Regional Health Props Q3 EPS $(0.52), Same YoY, Sales $4.22M Up From $4.14M YoY

Guess? Q3 2025 Adj. EPS $0.34 Down From $0.49 YoY, Sales $739.0M Up From $651.1M YoY

<p>The earnings results for <strong>Urban Outfitters</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) for Q3 were made public on Tuesday, November 26, 2024 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Urban Outfitters beat estimated earnings by 28.999999999999996%, reporting an EPS of $1.1 versus an estimate of $0.85.</p>
<p>Revenue was up $81.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>Last quarter the company beat on EPS by $0.24 which was followed by a 10.0% drop in the share price the next day.</p>
<p>Here's a look at Urban Outfitters's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1</td>
<td>0.51</td>
<td>0.73</td>
<td>0.82</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.24</td>
<td>0.69</td>
<td>0.69</td>
<td>0.88</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.34B</td>
<td>1.17B</td>
<td>1.49B</td>
<td>1.26B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.35B</td>
<td>1.20B</td>
<td>1.49B</td>
<td>1.28B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Urban Outfitters <a href="https://www.benzinga.com/quote/URBN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


URBN

Earnings Summary: Urban Outfitters Q3

<p><strong>HP</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) just disclosed its Q4 earnings on Tuesday, November 26, 2024 at 04:15 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>HP missed estimated earnings by 0.0%, reporting an EPS of $0.93 versus an estimate of $0.93.</p>
<p>Revenue was up $238.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>Last quarter the company missed on EPS by $0.03 which was followed by a 2.0% increase in the share price the next day.</p>
<p>Here's a look at HP's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.86</td>
<td>0.81</td>
<td>0.81</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.83</td>
<td>0.82</td>
<td>0.81</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>13.38B</td>
<td>12.60B</td>
<td>13.51B</td>
<td>13.81B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>13.52B</td>
<td>12.80B</td>
<td>13.19B</td>
<td>13.82B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for HP <a href="https://www.benzinga.com/quote/HPQ/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HP Earnings Report: Q4 Overview

<p><i>- SAN711 is a first-in-class, highly selective GABAA-α3 positive allosteric modulator</i></p>
<p><i>- Targeting initiation of Phase 2 study of SAN711 for the treatment of essential tremor in 2026</i></p>
<p>Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication the Company plans to pursue is development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body. Acadia is planning to initiate a Phase 2 study of SAN711 in essential tremor in 2026.</p>
<p>"Licensing SAN711 to expand our pipeline underscores our unwavering commitment to delivering innovative therapies for patients with central nervous system disorders," said Catherine Owen Adams, Chief Executive Officer. "Essential tremor is a condition that has not seen innovation in treatment for decades, creating a compelling opportunity to address a long-overlooked need. Our work with SAN711 will draw on our deep expertise in developing and commercializing cutting-edge treatments for neurological disorders."</p>
<p>Under the terms of the License Agreement, Saniona will receive US $28 million upfront plus potential milestone payments of up to US $582 million. In addition, Saniona is eligible to receive tiered royalties of mid-single digits to low double digits on net sales of commercial products that may result from development of SAN711. The potential milestone payments to Saniona consist of up to US $147 million subject to achievement of development and commercial milestones related to potential first and second indications, and up to US $435 million subject to achievement of thresholds of annual net sales of SAN711 worldwide. Acadia will lead further clinical development, regulatory submissions, and global commercialization efforts for SAN711 while also providing financial support for Saniona's ongoing Phase 1 study and preparations for Phase 2.</p>


ACAD

Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711; Under The Terms Of The License Agreement, Saniona Will Receive $28M Upfront Plus Potential Milestone Payments Of Up To $582M

<p>The quarterly cash dividend is payable on January 2, 2025 to stockholders of record as of the close of business on December 11, 2024. This is the first dividend of HP's 2025 fiscal year and represents an increase of 5% from the prior dividend.</p>


Comments

Zahav

ニュース

最新ニュース Zahav (OTC:ZAHA) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル